[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336759-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-336759-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","follow-up-strategies-after-trimodal-treatment-for-muscle-invasive-bladder-cancer-a-systematic-review","Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer - a systematic review","","Optimal follow-up strategies after trimodal treatment for muscle-invasive bladder cancer are essential for timely detection and management of relapse and treatment-related side effects. The review summarizes relapse patterns and risk factors, functional endpoints, and follow-up protocols. A systematic PubMed search and review of current guidelines and institutional surveillance approaches were conducted. Evidence from 43 studies covering 7,447 patients reports variable recurrence rates, bladder preservation over 5–10 years, and prognostic factors for inferior survival.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/follow-up-strategies-after-trimodal-treatment-for-muscle-invasive-bladder-cancer-a-systematic-review/336759/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/follow-up-strategies-after-trimodal-treatment-for-muscle-invasive-bladder-cancer-a-systematic-review/336759.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this systematic review?","Question",{"text":63,"@type":64},"To summarize follow-up strategies after trimodal treatment for muscle-invasive bladder cancer, focusing on relapse patterns, risk factors, functional outcomes, and follow-up protocols.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were studies selected for the review?",{"text":68,"@type":64},"Through a systematic PubMed literature search and review of current guidelines and institutional follow-up protocols for patients after trimodal therapy.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the review find about bladder preservation and recurrence?",{"text":72,"@type":64},"Bladder preservation was reported in about 60–85% after 5 years and 45–75% after 10 years, while recurrence rates in the urinary bladder varied widely (14–52%).",{"name":74,"@type":61,"acceptedAnswer":75},"Why is tailoring follow-up protocols considered important?",{"text":76,"@type":64},"Because available evidence is limited and surveillance intensity affects outcomes and resource use, so adapting follow-up to established risk factors may improve patient results and reduce unnecessary investigations.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},336759,1790072289,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":120,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","World Journal of Urology (2024) 42:527  \n[https://doi.org/10.1007/s00345-024-05196-7](https://doi.org/10.1007/s00345-024-05196-7)  \nFollow‑up strategies after trimodal treatment for muscle‑invasive bladder cancer: a systematic review  \nErnest Kaufmann1 · Stefanie Aeppli2 · Winfried Arnold3 · Panagiotis Balermpas4 · Jörg Beyer5 · Uwe Bieri6,7 · Richard Cathomas8 · Berardino de Bari9 · Marco Dressler10 · Daniel S. Engeler11 · Andreas Erdmann12 · Andrea Gallina13 · Silvia Gomez14 · Matthias Guckenberger4 · Thomas R. W. Herrmann15,16,17 ·  \nThomas Hermanns18 · Lucca Ilaria19 · Hubert John20 · Thomas M. Kessler21 · Jan Klein22,23 · Mohamed Laouiti24 · David Lauffer25 · Agostino Mattei1 · Michael Müntener26 · Daniel Nguyen27 · Philipp Niederberger28 · Alexandros Papachristofilou29 · Lukas Prause30 · Karsten Reinhardt31 · Emanuela Salati32 · Philippe Sèbe33 · Mohamed Shelan34 · Räto Strebel35 · Arnoud J. Templeton36 · Ursula Vogl37 · Marian S. Wettstein38 · Deborah Zihler39 · Thomas Zilli40 · Daniel Zwahlen41 · Beat Roth42 · Christian Fankhauser1  \nReceived: 8 May 2024 / Accepted: 19 July 2024 / Published online: 19 September 2024 © The Author(s) 2024  \nAbstract  \nPurpose Optimal follow-up strategies following trimodal treatment for muscle invasive bladder cancer play a crucial role in detecting and managing relapse and side-effects. This article provides a comprehensive summary of the patterns and risk factors of relapse, functional outcomes, and follow-up protocols.  \nMethods A systematic literature search on PubMed and review of current guidelines and institutional follow-up protocols after trimodal therapy were conducted.  \nResults Out of 200 identified publications, 43 studies (28 retrospective, 15 prospective) were selected, encompassing 7447 patients (study sizes from 24 to 728 patients). Recurrence rates in the urinary bladder varied between 14–52%; 3–16% were muscle-invasive while 11–36% were non-muscle invasive. Nodal recurrence occurred at 13–16% and distant metastases at 15–35% . After 5 and 10 years of follow-up, around 60–85% and 45–75% of patients could preserve their bladder, respectively. Various prognostic risk factors associated with relapse and inferior survival were proposed, including higher disease stage (> c/pT2), presence of extensive/multifocal carcinoma in situ (CIS), hydronephrosis, multifocality, histological subtypes, incomplete transurethral resection of bladder tumor (TURBT) and incomplete response to radio-chemotherapy. The analyzed follow-up guidelines varied slightly in terms of the number, timing, and types of investigations, but overall, the recommendations were similar.  \nConclusion Randomized prospective studies should focus on evaluating the impact of specific follow-up protocols on oncological and functional outcomes following trimodal treatment for muscle-invasive bladder cancer. It is crucial to evaluate personalized adaption of follow-up protocols based on established risk factors, as there is potential for improved patient outcomes and resource allocation.  \nKeywords Trimodal treatment · Trimodality · Bladder preservation · Functional outcomes · Oncological outcomes · Follow-up  \nIntroduction  \nBladder cancer poses a significant public health challenge, with approximately 500,000 new cases and 200,000 deaths reported annually worldwide [1] . Radical cystectomy represents the most commonly performed therapy  \nExtended author information available on the last page of the article  \nfor muscle-invasive bladder cancer but may be associated with relevant morbidity and functional impairment leading to a profound impact on patient’s quality of life [2, 3] . Trimodal treatment, consisting of transurethral resection of bladder tumor (TURBT) followed by chemoradiotherapy, has emerged as an alternative approach in selected patients [4]. Numerous studies have suggested comparable long-term survival outcomes between trimodal treatment and radical  \ncystectomy while mitigating perioperative morbidity and","cbCaif5Oe46YTgyq","https://ap.wps.com/l/cbCaif5Oe46YTgyq","pdf",677964,"English","# Abstract\n# Introduction\n# Evidence acquisition\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is the main purpose of this systematic review?\",\"answer\":\"To summarize follow-up strategies after trimodal treatment for muscle-invasive bladder cancer, focusing on relapse patterns, risk factors, functional outcomes, and follow-up protocols.\"},{\"question\":\"How were studies selected for the review?\",\"answer\":\"Through a systematic PubMed literature search and review of current guidelines and institutional follow-up protocols for patients after trimodal therapy.\"},{\"question\":\"What did the review find about bladder preservation and recurrence?\",\"answer\":\"Bladder preservation was reported in about 60–85% after 5 years and 45–75% after 10 years, while recurrence rates in the urinary bladder varied widely (14–52%).\"},{\"question\":\"Why is tailoring follow-up protocols considered important?\",\"answer\":\"Because available evidence is limited and surveillance intensity affects outcomes and resource use, so adapting follow-up to established risk factors may improve patient results and reduce unnecessary investigations.\"}]","Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer - a systematic review | PDF",1790016477,23,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3df75938e2d1be8be4d0fdbf75ba4ec.webp",983,1305,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad8933e180cab638a72b491215f56185.webp",982,1304,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d77db46fcbc5eabda57311d4644761c4.webp",981,1303,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8de230574720101b82d8d5bbb85443d0.webp",980,1301]